Trials / Completed
CompletedNCT02998476
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Parsaclisib | Parsaclisib once daily for 8 weeks followed by once weekly |
Timeline
- Start date
- 2017-03-02
- Primary completion
- 2019-02-22
- Completion
- 2021-02-05
- First posted
- 2016-12-20
- Last updated
- 2025-08-22
- Results posted
- 2020-04-24
Locations
70 sites across 11 countries: United States, Australia, Belgium, Canada, Czechia, France, Italy, Poland, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02998476. Inclusion in this directory is not an endorsement.